肿瘤抗原MAGE-A9和MAGE-A11在乳腺癌中的表达及其临床意义

目的探讨肿瘤抗原黑素瘤抗原基因A9(MAGE-A9)和MAGE-A11在乳腺癌组织中的表达,并分析其临床意义。方法选取2013年1月到2014年12月间的50例乳腺癌患者为A组,同期50例乳腺良性病变患者为B组,50名健康者为C组。采取免疫组化学染色法检测各组MAGE-A9和MAGE-A11表达,分析其临床意义。结果A组中MAGE-A9和MAGE-A11表达阳性率分别为48.0%、64.0%;B组和C组中MAGE-A9和MAGE-A11无表达,三组间差异有统计学意义(P0.05);MAGE-A9和MAGE-A11表达与ER、HER-2相关,差异有统计学意义(P0.05)。结论临床中MAGE-A9和MAGE-A11是肿瘤特异性抗原,在乳腺癌中得到表达,且与HER-2、ER表达具有相关性,在临床中具有重要的意义。     

ezrin在乳腺癌中的表达及其临床意义

目的 探讨乳腺癌组织中ezrin蛋白的表达及其临床意义.方法 应用免疫组化S-P方法,检测63例乳腺癌组织中ezrin的表达情况.结果 ezrin总的表达率为55.56%(35/63),ezrin表达率随着淋巴结转移增多和临床分期的增高而升高(χ2分别为7.718、6.760,P分别为0.005、0.009).无病生存时间在5年以上患者的ezrin表达率[33.33%(10/30)]显著低于无病生存时间不足5年(远处转移)或5年内死亡的患者(75.76%,25/33,χ2=11.455,P=0.001),但是ezrin的表达和肿瘤大小、月经及年龄无相关性(χ2分别为0.060、0.423、0.319,P均>0.05).结论 检测ezrin在乳腺癌中的表达可能有助于对其预后的判断.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

MAGE-A9在乳腺癌组织中的表达及临床意义

目的检测MAGE-A9在乳腺癌中的表达情况,分析其与乳腺癌临床病理特征的关系。方法在组织芯片上(70例乳腺癌标本及20例癌旁对照标本)进行免疫组化检测,使用Cox回归法及Kaplan-Meier生存分析法进行乳腺癌病人的预后评估。结果免疫组化结果显示乳腺癌中的MAGE-A9表达明显高于癌旁对照组的表达(P0.05)。MAGE-A9的表达与乳腺癌病人的肿瘤组织学分级、淋巴结转移、远处转移及TNM分期有重要关联(P均0.05)。生存分析显示MAGE-A9阳性、TNM分期与乳腺癌病人预后关系密切,MAGE-A9高表达提示病人预后不良。结论 MAGE-A9在乳腺癌组织中异常高表达且MAGE-A9的表达与乳腺癌病人的多项重要临床指标相关。MAGE-A9可作为乳腺癌病人预后的独立危险因素。     

dCTP焦磷酸酶在乳腺癌组织中的表达情况及临床意义研究

目的 分析dCTP焦磷酸酶(DCTPP1)在乳腺癌组织中的表达情况及其临床意义.方法 选取2016年6月至2017年12月在本院行手术治疗乳腺癌的女性患者82例,每例标本均取癌组织为癌组织组,取距癌边缘5cm以上的正常组织为癌旁组织组.收集患者的临床及随访资料,包括年龄、肿瘤分级、T分期、淋巴结转移情况、组织类型、雌激...     

谷胱甘肽转移酶π在乳腺癌中的表达及其临床意义

目的 探讨乳腺癌组织中谷胱甘肽转移酶(GSTpi)的表达与预后的关系.方法 用免疫组化方法检测120名女性乳腺癌患者CSTpi的表达情况,并与患者年龄、肿瘤大小、组织学分级、腋淋巴结转移及临床分期进行相关分析.统计学:采用X2检验,相关性检验采用秩相关统计法.结果 谷胱甘肽转移酶(GSTpi)的表达与乳腺癌肿瘤大小、组织学分级及腋淋巴结转移率、临床分期密切相关(P＜0.05).结论 谷胱甘肽转移酶(GSTpi)与乳腺癌预后关系密切.乳腺癌组织中CSTpi的存在是一个预后差的预后指标.     

C-erbB-2在人乳腺癌中的表达及其临床意义

目的 研究癌基因C-erbB-2在人乳腺癌中的表达及其临床预后价值。方法 应用免疫组化方法检测157例临床及随访资料完整的乳腺癌标本中C-erbB-2的表达情况，用Cox回归分析其预后意义。结果 C-erbB-2阳性表达率为40．8％。全组总的五年生存率为54．99％。C-erbB-2表达与患者年龄、月经状况、肿瘤大小、TNM分期和腋淋巴结状态相关。C-erbB-2表达阳性组的生存率低于阴性组(P=0．0011)。多因素Cox回归分析显示，C-erbB-2不同表达和TNM分期2项指标反映乳腺癌预后情况，其危险度分别为2．770及1．661。结论 C-erbB-2是一个十分有价值的乳腺癌预后指标，其阳性患者的预后较差。     

ki67在乳腺癌组织中的表达及其临床意义

目的检测ki67在乳腺癌组织中的表达并探讨其与病理因素的关系。方法应用免疫组化法检测166例乳腺癌组织中ki67的表达,分析其与病理因素的关系。结果阳性表达率为79．52％;过表达率在腋淋巴结转移、组织学分级Ⅲ级、原发肿瘤〉2cm者中较高,而与年龄无关。结论ki67在乳腺癌组织中的表达较高,与腋窝淋巴结转移,原发肿瘤大小,组织学分级的关系密切,检测具有实际的临床意义。     

血管内皮生长因子在乳腺癌中的表达及临床意义

目的 研究血管内皮生长因子(VEGF)在乳腺癌中的表达及临床意义.方法 应用S-P免疫组化方法检测60例乳腺癌组织(乳腺癌组)和20例乳腺良性病变组织(乳腺纤维腺瘤组)中VEGF的表达情况,结合临床及病理形态学资料进行统计分析.结果 乳腺癌组中VEGF阳性表达49例;乳腺纤维腺瘤组中VEGF阳性表达4例;2组VEGF阳性率比较差异有统计学意义(81.67％与20.00％,u=4.39,P=0.000).VEGF的表达与淋巴结转移、肿瘤大小、组织学分级和临床分期呈正相关(rs =0.357、0.594、0.680、0.540,P均＜0.05),与患者年龄、雌激素、孕激素受体情况无相关性(P均＞0.05).结论 VEGF可能与乳腺癌的进展、转移及预后有关,作为独立的指标对判定预后具有参考意义.     

5脂氧化酶在乳腺癌中的表达及临床意义

目的 探讨5脂氧化酶(5-LOX)在乳腺癌组织中的表达及临床意义.方法 采用免疫组化方法检测74例乳腺癌(乳腺癌组)、24例癌旁组织(癌旁组)及18例正常乳腺组织(对照组)中5-LOX蛋白的表达;并分析其与临床病理特征的相关性.结果 乳腺癌组74例中5-LOX阳性表达64例,明显高于癌旁组24例中阳性表达4例及正常乳腺组织18例中阳性表达2例(86.5％、16.7％及11.1％,x2=70.029,P＜0.01);5-LOX表达与肿瘤大小(Rs =0.375,P＜0.001)、组织学分级(Rs=0.236,P＜0.05)、临床分期(Rs=0.249,P＜0.05)、淋巴结转移(Rs =0.355,P＜0.01)呈正相关,与患者年龄、雌激素及孕激素受体情况无关.结论 5-LOX蛋白与乳腺癌的发生、发展和转移有关,有可能作为独立指标判断乳腺癌预后.     

Ki67在乳腺癌组织中的表达及其临床意义研究

目的探讨乳腺癌组织Ki67表达水平及其与疾病分型、患者预后等的相关性。方法收集2013年1月至2015年12月于本院治疗的93例乳腺癌患者及20例乳腺良性疾病患者临床资料,分析Ki67指数与疾病病理参数及实验室指标的相关性。结果 93例乳腺癌患者Ki67指数水平为1%~90%,中位数为21.65%。乳腺癌组织学分级、肿瘤直径、人表皮生长因子受体2(HER2)表达状态与Ki67指数相关(P0.05),年龄、绝经状态、肿瘤TNM分期、腋窝淋巴结转移状态、雌激素受体(ER)及孕激素受体(PR)表达状态与Ki67指数无关(P0.05)。三阴性乳腺癌、非三阴性乳腺癌及乳腺良性疾病患者Ki67指数中位数依次为30.15%、20.26%、4.67%,三者间Ki67指数比较差异有统计学意义(P0.05)。Ki67指数水平与乳腺癌分型相关(P0.05),与患者血细胞比容和血钾浓度水平相关(P0.05)。结论 Ki67指数联合其他指标可用于乳腺癌诊治及患者预后判断,具有一定的临床应用价值。